Decheng Capital LLC
Top Portfolio Positions
13 positions ·
$647,433,708 total
· as of Mar 31, 2026
| Ticker | Company | Shares | Value (USD) | % of Portfolio | Open |
|---|---|---|---|---|---|
| CGON |
CG Oncology, Inc.
Healthcare
|
6,371,669 | $431,234,557 | 66.61% | |
| NUVB |
Nuvation Bio Inc.
Healthcare
|
25,954,439 | $111,344,543 | 17.20% | |
| UPB |
Upstream Bio, Inc.
Healthcare
|
2,724,868 | $24,523,812 | 3.79% | |
| ACRS |
Aclaris Therapeutics, Inc.
Healthcare
|
4,041,736 | $15,156,510 | 2.34% | |
| AARD |
Aardvark Therapeutics, Inc.
Healthcare
|
3,917,299 | $14,768,217 | 2.28% | |
| NAMS |
NewAmsterdam Pharma Co N.V.
Healthcare
|
325,057 | $10,405,074 | 1.61% | |
| RCUS |
Arcus Biosciences, Inc.
Healthcare
|
477,819 | $10,320,890 | 1.59% | |
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
93,500 | $9,092,875 | 1.40% | |
| EQ |
Equillium, Inc.
Healthcare
|
4,447,308 | $8,894,616 | 1.37% | |
| BYSI |
BeyondSpring Inc.
Healthcare
|
3,800,702 | $6,233,151 | 0.96% |
Portfolio Trend
10 quarters · across all stocks
Holdings in BYSI
Shares Held
Position Value (USD)
10 quarters on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,233,151 | 3,800,702 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $6,195,144 | 3,800,702 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $7,757,848 | 4,286,104 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $10,648,980 | 4,531,481 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $7,006,604 | 4,882,651 | Shares | Sole | 2025-05-08 | |
| 2024-12-31 | $7,958,721 | 4,882,651 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $11,354,147 | 4,958,143 | Shares | Sole | 2024-11-15 | |
| 2024-06-30 | $11,899,543 | 4,958,143 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $17,700,570 | 4,958,143 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $4,462,328 | 4,958,143 | Shares | Sole | 2024-02-12 | |
| No 13F history on record for this holder in this stock. | ||||||